We set an R&D center which covers 1800 ㎡ in JSLS Nanjing City. Our center is divided into R&D department and Pilot scale department, which can complete pilot scale requirements. We have a energetic and experienced team equipped with advanced organic synthesis and analysis of testing instruments and equipment, which also passed the ISO9001 quality system.
Our R&D center is focused on targeted anti-tumor products,anti-cardiovascular products, and anti-diabetes products.
Our main products are:
(1)Anti-tumor products—Gefitinib、Erlotinib、Dasatinib、Lapatinib、Sunitinib、Nilotinib、Sorafenib 、Vandetanib、Axitinib、Afatinib、Pazopanib、Ibrutinib、 Lenvatinib、Palbociclib、Osimertinib、Crizotinib、Cabozantinib、Bosutinib、Regorafenib、Ceritinib、Nintedanib、Lenalidomide .ect;
(2)Anti-Cardiovascular products---Apixaban, Rivaroxaban, Prasugrel, Ticagrelor, Dabigatran , Ezetimibe and so on.
(3)Anti-diabetic products--
DPP-4:Alogliptin, Linagliptin, Vildagliptin, Sitagliptin, Teneligliptin, Saxagliptin, etc.
SGLT-2:Dapagliflozin、Canagliflozin、Empagliflozin、Ipragliflozin etc.
備案序号:蘇ICP備18016471号
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
Toocle Copyright Notice